Skip to main content

Table 1 Clinical characteristics of AEG patients in the training and internal validation set

From: A novel risk score system for prognostic evaluation in adenocarcinoma of the oesophagogastric junction: a large population study from the SEER database and our center

Clinical features Overall Training set Internal validation set Statistical test p-value
Sample size 1930 1544 386  
Survival time (months, median [IQR]) 24.00 [13.00, 43.00] 24.00 [13.00, 43.00] 23.00 [13.00, 42.00] 0.826
Survival status (%)     0.473
Alive 994 (51.5) 802 (51.9) 192 (49.7)  
Dead 936 (48.5) 742 (48.1) 194 (50.3)  
Age (years, median [IQR]) 63.00 [55.00, 70.00] 64.00 [56.00, 71.00] 63.00 [55.00, 70.00] 0.396
Sex (%)     0.155
Female 356 (18.4) 295 (19.1) 61 (15.8)  
Male 1574 (81.6) 1249 (80.9) 325 (84.2)  
Histologic grade (%)     0.952
Well differentiated 120 (6.2) 95 (6.2) 25 (6.5)  
Moderately differentiated 728 (37.7) 582 (37.7) 146 (37.8)  
Poorly differentiated 1051 (54.5) 841 (54.5) 210 (54.4)  
Undifferentiated 31 (1.6) 26 (1.7) 5 (1.3)  
Tumor size (%)     0.203
≤1 cm 155 (8.0) 120 (7.8) 35 (9.1)  
1-2 cm 294 (15.2) 235 (15.2) 59 (15.3)  
2-3 cm 356 (18.4) 278 (18.0) 78 (20.2)  
3-4 cm 337 (17.5) 259 (16.8) 78 (20.2)  
4-5 cm 276 (14.3) 228 (14.8) 48 (12.4)  
> 5 cm 512 (26.5) 424 (27.5) 88 (22.8)  
pStage (%)     0.244
I 373 (19.3) 286 (18.5) 87 (22.5)  
II 472 (24.5) 378 (24.5) 94 (24.4)  
III 986 (51.1) 803 (52.0) 183 (47.4)  
IV 99 (5.1) 77 (5.0) 22 (5.7)  
pT stage (%)     0.209
T1 389 (20.2) 297 (19.2) 92 (23.8)  
T2 270 (14.0) 215 (13.9) 55 (14.2)  
T3 1136 (58.9) 924 (59.8) 212 (54.9)  
T4 135 (7.0) 108 (7.0) 27 (7.0)  
pN stage (%)     0.5
N0 716 (37.1) 562 (36.4) 154 (39.9)  
N1 632 (32.7) 510 (33.0) 122 (31.6)  
N2 344 (17.8) 283 (18.3) 61 (15.8)  
N3 238 (12.3) 189 (12.2) 49 (12.7)  
pM stage (%)     0.661
M0 1831 (94.9) 1467 (95.0) 364 (94.3)  
M1 99 (5.1) 77 (5.0) 22 (5.7)  
Radiation status (%)     0.267
No/Unknown 859 (44.5) 677 (43.8) 182 (47.2)  
Yes 1071 (55.5) 867 (56.2) 204 (52.8)  
Chemotherapy status (%)     0.201
No/Unknown 542 (28.1) 423 (27.4) 119 (30.8)  
Yes 1388 (71.9) 1121 (72.6) 267 (69.2)  
Positive LNs number (median [IQR]) 1.00 [0.00, 3.00] 1.00 [0.00, 3.00] 0.00 [0.00, 3.00] 0.669
Examined LNs number (median [IQR]) 16.00 [10.00, 23.00] 16.00 [10.00, 23.00] 16.00 [10.00, 23.00] 0.533
Ratio of metastasis LNs (median [IQR]) 0.03 [0.00, 0.20] 0.03 [0.00, 0.22] 0.00 [0.00, 0.18] 0.369
  1. * The statistical differences between two groups were tested by χ2 or Fisher exact tests, if appropriate. IQR: interquartile range. LNs: lymph nodes